Since ZEB1 expression in breast cancer is inversely linked to ERα protein levels, downregulating ZEB1 significantly increases the responsiveness of breast cancer cells to estrogen inhibitor therapy using tamoxifen and fulvestrant under in vitro and in vivo conditions. This evidence concerns the gene ZEB1 and breast carcinoma.